Intravitreal Dexamethasone Implant in Autoimmune Retinopathy

Fernando Longhi Bordin; Carolina da Silva Mengue; Manuel Augusto Pereira Vilela

doi:10.1155/2023/5670538

Intravitreal Dexamethasone Implant in Autoimmune Retinopathy

Case Rep Ophthalmol Med. 2023 Mar 31:2023:5670538. doi: 10.1155/2023/5670538. eCollection 2023.

Authors

Fernando Longhi Bordin¹, Carolina da Silva Mengue¹, Manuel Augusto Pereira Vilela²

Affiliations

¹ Institute Ivo Corrêa-Meyer, Porto Alegre, Brazil.
² Federal University of Health Sciences of Porto Alegre, Brazil.

Abstract

Purpose: To describe the results of an intravitreal dexamethasone implant in managing autoimmune retinopathy (AIR).

Methods: Two patients affected by AIR underwent intravitreal dexamethasone implantation and were followed by ocular coherence tomography, visual fields, and electroretinography.

Results: The patients showed an interruption of the functional losses and remained stable with semestral injections.

Conclusion: AIR is a complex condition with no standard treatment. The use of dexamethasone could be a valid option.

Publication types

Case Reports